Advertisement
Advertisement

GMAB

GMAB logo

Genmab A/S ADS

32.60
USD
Sponsored
-0.75
-2.24%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

32.62

+0.02
+0.06%

GMAB Earnings Reports

Positive Surprise Ratio

GMAB beat 26 of 39 last estimates.

67%

Next Report

Next Week
Date of Next Report
Feb 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.05B
/
$3.91
Implied change from Q3 25 (Revenue/ EPS)
+2.69%
/
-39.47%
Implied change from Q4 24 (Revenue/ EPS)
+13.95%
/
-54.11%

Genmab A/S ADS earnings per share and revenue

On Nov 06, 2025, GMAB reported earnings of 6.46 USD per share (EPS) for Q3 25, beating the estimate of 4.73 USD, resulting in a 36.36% surprise. Revenue reached 1.02 billion, compared to an expected 1.01 billion, with a 1.09% difference. The market reacted with a -0.62% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of 3.91 USD, with revenue projected to reach 1.05 billion USD, implying an decrease of -39.47% EPS, and increase of 2.69% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Genmab A/S ADS reported EPS of $6.46, beating estimates by 36.36%, and revenue of $1.02B, 1.09% above expectations.
The stock price moved down -0.62%, changed from $28.84 before the earnings release to $28.66 the day after.
The next earning report is scheduled for Feb 05, 2026.
Based on 10 analysts, Genmab A/S ADS is expected to report EPS of $3.91 and revenue of $1.05B for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement